drugsTreatmentPhase 3

AL8326

AL8326 is an experimental small-molecule drug from Advenchen Pharmaceuticals in phase 3 trials for small-cell lung cancer, non-small-cell lung cancer and renal cell carcinoma, with its target not yet stated publicly.

AL8326 is a small-molecule drug developed by Advenchen Pharmaceuticals and Advenchen Laboratories Nanjing. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: 10mg/tablet, Oral administration, once daily. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06247605 (A Phase IIII Study of AL8326 in Small Cell Lung Cancer), in small-cell lung cancer, non-small-cell lung cancer and renal cell carcinoma. The largest, NCT06247605, plans to enrol 243 participants with primary completion expected 2028-07. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.

How targeted therapy works, step by step · animated schematic, not to scale; chosen from the modality "small molecule"

Targeted Therapy →

Modality

small molecule

Mechanism

Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

Trials

top

Trials recruiting now

Recruiting trials near you · live from ClinicalTrials.gov

AL8326

intervention: AL8326

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.